Companies › Prilenia
1 active drug program in 3 registered trials: 2 Phase 3, 1 Phase 2; Neurology; next expected readout Mar 2028.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Pridopidine Dopamine D2 receptor modulator | DRD2 | Phase 3 | Amyotrophic Lateral Sclerosis; Huntington Disease | Mar 2028 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT04297683 | Pridopidine | Phase 2 | Amyotrophic Lateral Sclerosis | Neurology | Jul 2027 |
| NCT07322003 | Pridopidine | Phase 3 | Amyotrophic Lateral Sclerosis | Neurology | Mar 2028 |
| NCT07609108 | Pridopidine | Phase 3 | Huntington Disease | Neurology | Jun 2028 |
MDD US Operations, LLC a subsidiary of Supernus Pharmaceuticals Ambros Therapeutics Cerevance Green Valley (Shanghai) Pharmaceuticals CereMark Pharma
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.